All lobbying filings

Sanofi US Services Inc.

Sanofi US Services Inc. filed a Q4 report for Sanofi US Services Inc. on January 20, 2026.

Lobbying for Sanofi US Services Inc.

As filed: SANOFI US SERVICES INC. for SANOFI US SERVICES INC.

All filings by Sanofi US Services Inc. · Everything Sanofi US Services Inc. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$1,100,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Health Issues

340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Price Negotiations - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 830 (118th) HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5143 (118th) Vaccines Access Improvement Act; HR 5376: Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues.

Medicare/Medicaid

340B; Medicare Negotiation, and Most Favored Nation.

Trade (domestic/foreign)

Supply Chain Issues; and Importation issues.

Taxation/Internal Revenue Code

Supply Chain issues; and Vaccine Injury Compensation Program.

S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property.

Manufacturing

Insulin; Taxes- General Issues; Vaccine - General Issues; Pharmacy Benefits Managers (PBMs); and Type 1 Diabetes Screening.

Bills named in this filing 18

H.R. 7174
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S. 832
EPIC Act of 2025
H.R. 1
One Big Beautiful Bill Act
H.R. 830
HELP Copays Act
H.R. 2880
Protecting Patients Against PBM Abuses Act
H.R. 5143
Vaccine Access Improvement Act of 2023
H.R. 5376
Impacts and Outcomes for Health Career Training Act
H.R. 5539
ORPHAN Cures Act
H.R. 7834
Safe Cloud Storage Act
S. 864
HELP Copays Act
S. 1339
Pharmacy Benefit Manager Reform Act
S. 1375
HELP Copays Act
S. 1542
DRUG Act
S. 2027
Prescription Information Modernization Act of 2025
S. 4504
SCREEN for Type 1 Diabetes Act of 2024
H.R. 8698
SCREEN for Type 1 Diabetes Act of 2024
S. 43
Skinny Labels, Big Savings Act
S. 2276
ETHIC Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.